Inhibikase Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Inhibikase Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 3,032% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+79%Cash, after subtracting all debt, equals 79% of its market value (net cash).
Higher than 84% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Inhibikase Therapeutics, Inc. made a loss over the last year. Inhibikase Therapeutics, Inc. owes $0.06 for every $1 it owns. Inhibikase Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossInhibikase Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.48The share price is 1.48 times Inhibikase Therapeutics, Inc.'s book value per share, lower than 68% of Healthcare companies in United States.
Market cap
$227 MThe total market value of all of Inhibikase Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$153 MWhat Inhibikase Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.10Net worth divided by the number of shares. The share price of $1.63 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
-52.0%Inhibikase Therapeutics, Inc. lost 52.0% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
Owes vs Owns
0.06×Inhibikase Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Dividend yield
NoneInhibikase Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossInhibikase Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashInhibikase Therapeutics, Inc. held $179 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Inhibikase Therapeutics, Inc.: $227 M ÷ $153 M (30 Jun 2026) = 1.5.
What is Inhibikase Therapeutics, Inc.'s return on equity?
Inhibikase Therapeutics, Inc. lost 52.0% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
How much does Inhibikase Therapeutics, Inc. owe compared with what it owns?
Inhibikase Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Does Inhibikase Therapeutics, Inc. pay a dividend?
No. Inhibikase Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.